查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070480

CRISPR療法市場規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測

CRISPR Therapeutics Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

CRISPR療法市場成長要素

2025年全球CRISPR療法市場規模為1.16億美元，預計將從2026年的2.4億美元成長至2034年的63億美元，在預測期間（2026-2034年）複合年成長率高達50.45%。北美市場佔主導地位，預計2025年市場佔有率將達到71.29%，這得益於CRISPR療法的早期商業化、強力的監管支持以及先進的基因治療基礎設施。

CRISPR療法透過在DNA層級直接編輯遺傳物質，為疾病治療提供了一種革命性的方法。與主要針對症狀的傳統療法不同，基於CRISPR的療法直擊遺傳疾病的根本原因。首個核准的CRISPR基因編輯療法CASGEVY的商業性成功，以及基因編輯研究投入的增加、遞送技術的改進和針對罕見病和慢性病的臨床研發管線的不斷擴展，推動了這一市場快速成長。

市場趨勢

基因編輯技術的進步正在推動創新。

基因編輯平台的技術正快速發展，包括鹼基編輯、新一代CRISPR系統以及改進的遞送機制。這些創新提高了編輯精度，同時減少了脫靶效應，使開發者能夠針對更廣泛的疾病進行治療，包括肝病、心血管疾病、代謝性疾病和遺傳性疾病。

2026 年 3 月，Beam Therapeutics 公佈了 BEAM-302（一種治療 α-1 抗胰蛋白酶缺乏症的標靶）的 1/2 期臨床數據，凸顯了先進的 CRISPR 技術日益成長的潛力。

市場促進因素

針對罕見遺傳疾病的臨床試驗數量增加

針對罕見遺傳疾病的臨床試驗數量增加是推動成長要素。 CRISPR療法有望透過一次治療徹底治癒疾病，因此對於治療選擇有限的疾病而言，它極具吸引力。

2025 年 9 月，Interior Therapeutics 完成了評估 rombogran dicrumeran 治療遺傳性血管性水腫的 3 期 HAELO 試驗的患者招募工作，顯示其在臨床開發方面取得了強勁的進展。

擴大監管支持

監管機構正透過快速核准機制和特殊認定，日益支持創新基因編輯療法。這種支持降低了研發風險，並加速了基於CRISPR技術的療法的商業化。

市場限制因素

高昂的醫療費用

CRISPR療法涉及複雜的生產流程、個人化細胞採集、基因改造、預處理方案和長期監測。這些因素導致治療成本高昂，為保險報銷帶來挑戰，尤其是在開發中國家。

儘管臨床上取得了成功，但由於需要針對不同國家製定報銷協議，大規模應用仍然進展緩慢。

市場機遇

人們越來越接受一次療程就能治癒疾病的治療方法。

醫療專業人員和患者對根治性治療方法的支持日益成長。完善的管理體系、廣泛的監管支援以及持續的產品線拓展，為CRISPR技術研發公司進入新的疾病領域和病患群體創造了重要機會。

市場挑戰

基因編輯引發的倫理問題

圍繞人類基因組編輯的倫理爭論仍然是一項重大挑戰。人們對長期安全性、基因編輯技術的濫用以及未來可能應用於生殖細胞的擔憂，持續受到監管機構和公眾的密切關注。

細分分析

副產品

作為首個核准的 CRISPR/Cas9 基因編輯療法，CASGEVY 預計到 2025 年將佔最大的市場佔有率。保險覆蓋範圍的擴大和治療中心的擴張將繼續推動其普及。

適應症

到 2025 年，由於患者人數眾多以及對突破性療法的高需求，鐮狀細胞疾病領域佔了市場主導地位。

按年齡層

到 2025 年，成人市場將佔最大的市場佔有率，因為目前許多核准的治療方法和臨床計畫都針對成年患者。

最終用戶

由於醫院擁有幹細胞採集、基因編輯、輸液和治療後監測所需的現有專業基礎設施，因此醫院領域推動了市場發展。

區域展望

北美洲

預計北美將繼續保持其作為區域市場的領先地位，到 2025 年市場規模預計將達到 8,270 萬美元。該地區憑藉其先進的醫療保健基礎設施、強大的研究能力以及對基因編輯療法的早期應用，發揮著重要作用。

美國市場

預計到 2026 年，美國 CRISPR 療法市場規模將達到約 1.469 億美元，佔全球銷售額的近 61.2%。

歐洲

預計歐洲在預測期內將以 51.75% 的複合年成長率成長。保險覆蓋範圍的擴大和 CASGEVY 服務取得管道的增加正在推動該地區的成長。

亞太地區

由於亞太地區患者人數眾多、醫療保健投資不斷增加以及對先進基因療法的興趣日益濃厚，預計該地區將錄得最高的成長率。

拉丁美洲、中東和非洲

預計這些地區將經歷顯著成長，這得益於人們對基因編輯療法的認知不斷提高、醫療保健服務覆蓋範圍擴大以及政府對創新療法的支持。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 大型公司管道分析
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 主要國家和地區的監管趨勢
  • CRISPR技術的進步

第5章：2021-2034年全球CRISPR治療藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品分類。
    • CASGEVY
    • 其他
  • 市場分析、洞察與預測：按指標
    • 鐮狀細胞貧血症
    • 輸血依賴性BETA-地中海貧血
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專業治療中心
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美CRISPR治療藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲 CRISPR 治療藥物市場分析、洞察與預測（2021-2034 年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第8章：亞太地區CRISPR治療藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太國家

第9章：拉丁美洲 CRISPR 療法市場分析、洞察與預測（2021-2034 年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲 CRISPR 療法市場分析、洞察與預測（2021-2034 年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Vertex Pharmaceuticals Incorporated
    • Intellia Therapeutics, Inc.
    • Beam Therapeutics.
    • Eli Lilly and Company（Verve Therapeutics, Inc.）
    • CRISPR Therapeutics
    • Editas Medicine
Product Code: FBI116021

Growth Factors of CRISPR therapeutics Market

The global CRISPR therapeutics market size was valued at USD 116.0 million in 2025 and is projected to grow from USD 240.0 million in 2026 to USD 6,300.0 million by 2034, exhibiting a remarkable CAGR of 50.45% during the forecast period (2026-2034). North America dominated the market with a 71.29% market share in 2025, supported by early commercialization of CRISPR-based therapies, strong regulatory backing, and advanced gene therapy infrastructure.

CRISPR therapeutics represent a revolutionary approach to disease treatment by directly editing genetic material at the DNA level. Unlike conventional therapies that primarily manage symptoms, CRISPR-based treatments target the root cause of genetic disorders. The market is witnessing rapid expansion due to the commercial success of CASGEVY, the first approved CRISPR gene-editing therapy, alongside growing investments in gene-editing research, improved delivery technologies, and expanding clinical pipelines targeting rare and chronic diseases.

Market Trends

Advancements in Gene-Editing Technologies Driving Innovation

The market is witnessing rapid technological advancements in gene-editing platforms, including base editing, next-generation CRISPR systems, and improved delivery mechanisms. These innovations are enhancing editing precision while reducing off-target effects, allowing developers to target a broader range of diseases such as liver disorders, cardiovascular conditions, metabolic diseases, and inherited genetic disorders.

In March 2026, Beam Therapeutics reported promising Phase 1/2 clinical data for BEAM-302 targeting alpha-1 antitrypsin deficiency, highlighting the growing potential of advanced CRISPR technologies.

Market Drivers

Rising Clinical Trials for Rare Genetic Diseases

The increasing number of clinical trials targeting rare genetic disorders is a major growth driver. CRISPR therapies offer the potential for one-time curative treatments, making them highly attractive for conditions with limited treatment options.

In September 2025, Intellia Therapeutics completed enrollment in the Phase 3 HAELO study evaluating lonvoguran ziclumeran for hereditary angioedema, demonstrating strong momentum in clinical development.

Expanding Regulatory Support

Regulatory agencies are increasingly supporting innovative gene-editing therapies through expedited pathways and special designations. This support reduces development risks and accelerates commercialization opportunities for CRISPR-based treatments.

Market Restraints

High Treatment Costs

CRISPR therapies involve complex manufacturing processes, personalized cell collection, genetic modification, conditioning regimens, and long-term monitoring. These factors contribute to high treatment costs and create reimbursement challenges, particularly in developing economies.

The need for country-specific reimbursement agreements continues to slow large-scale adoption despite clinical success.

Market Opportunities

Growing Acceptance of One-Time Curative Therapies

Healthcare providers and patients are increasingly embracing curative treatment approaches. Improved delivery systems, broader regulatory support, and ongoing pipeline expansion create significant opportunities for CRISPR developers to enter new disease areas and patient populations.

Market Challenges

Ethical Concerns Surrounding Gene Editing

Ethical debates regarding human genome editing remain a significant challenge. Concerns related to long-term safety, misuse of gene-editing technologies, and potential future germline applications continue to attract regulatory scrutiny and public attention.

Segmentation Analysis

By Product

The CASGEVY segment held the largest market share in 2025 due to its status as the first approved CRISPR/Cas9 gene-editing therapy. Growing reimbursement approvals and treatment center expansion continue to support adoption.

By Indication

The sickle cell disease segment dominated the market in 2025 owing to its large patient population and strong demand for transformative treatment options.

By Age Group

The adult segment accounted for the largest market share in 2025 as most currently approved therapies and clinical programs focus on adult patients.

By End User

The hospitals segment led the market due to the specialized infrastructure required for stem cell collection, gene editing, infusion procedures, and post-treatment monitoring.

Regional Outlook

North America

North America remained the leading regional market with a value of USD 82.7 million in 2025. The region benefits from advanced healthcare infrastructure, strong research capabilities, and early adoption of gene-editing therapies.

U.S. Market

The U.S. CRISPR therapeutics market is projected to reach approximately USD 146.9 million in 2026, accounting for nearly 61.2% of global revenue.

Europe

Europe is projected to grow at a CAGR of 51.75% during the forecast period. Expanding reimbursement agreements and increasing access to CASGEVY are supporting regional growth.

Asia Pacific

Asia Pacific is expected to register the fastest growth rate owing to its large patient population, increasing healthcare investments, and growing interest in advanced gene therapies.

Latin America and Middle East & Africa

These regions are expected to experience notable growth driven by increasing awareness of gene-editing therapies, expanding healthcare access, and government support for innovative treatments.

Competitive Landscape

The CRISPR therapeutics market is highly concentrated, with leading companies focusing on commercial expansion, clinical pipeline advancement, and strategic partnerships.

Key Companies Profiled

  • Vertex Pharmaceuticals Incorporated (U.S.)
  • Intellia Therapeutics, Inc. (U.S.)
  • Beam Therapeutics (U.S.)
  • Eli Lilly and Company (Verve Therapeutics, Inc.) (U.S.)
  • CRISPR Therapeutics (Switzerland)
  • Editas Medicine (U.S.)

Key Industry Developments

  • March 2026: Intellia Therapeutics received FDA clearance to continue the Phase 3 MAGNITUDE trial for nexiguran ziclumeran.
  • February 2026: Beam Therapeutics expanded its liver-targeted gene-editing portfolio with BEAM-304 for phenylketonuria.
  • January 2026: Vertex secured a reimbursement agreement in England for CASGEVY.
  • September 2025: CRISPR Therapeutics and Sirius Therapeutics initiated Phase 2 studies for SRSD107 in Europe.
  • May 2025: CRISPR Therapeutics entered a strategic collaboration with Sirius Therapeutics to develop novel gene-based medicines.

Conclusion

The CRISPR therapeutics market is entering a transformative growth phase, driven by the commercial success of CASGEVY, rapid advancements in gene-editing technologies, expanding clinical pipelines, and strong regulatory support. The market is expected to grow from USD 116.0 million in 2025 to USD 240.0 million in 2026 and reach USD 6,300.0 million by 2034, reflecting the increasing adoption of one-time curative therapies. While high treatment costs and ethical concerns remain challenges, continued innovation, expanding reimbursement coverage, and growing clinical success are expected to position CRISPR therapeutics as a major pillar of future precision medicine.

Segmentation By Product, Indication, Age Group, End User, and Region

By Product * CASGEVY

  • Others

By Indication * Sickle Cell Disease

  • Transfusion-Dependent Beta Thalassemia
  • Others

By Age Group * Pediatric

  • Adult

By End User * Hospitals

  • Specialty Treatment Centers
  • Others

By Region * North America (By Product, Indication, Age Group, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Product, Indication, Age Group, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, Indication, Age Group, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Product, Indication, Age Group, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Indication, Age Group, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Technological Advancements in CRISPR Technologies

5. Global CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. CASGEVY
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Sickle Cell Disease
    • 5.2.2. Transfusion-Dependent Beta Thalassemia
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adult
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Treatment Centers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. CASGEVY
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Sickle Cell Disease
    • 6.2.2. Transfusion-Dependent Beta Thalassemia
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adult
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Treatment Centers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. CASGEVY
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Sickle Cell Disease
    • 7.2.2. Transfusion-Dependent Beta Thalassemia
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adult
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Treatment Centers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Rest of Europe

8. Asia Pacific CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. CASGEVY
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Sickle Cell Disease
    • 8.2.2. Transfusion-Dependent Beta Thalassemia
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adult
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Treatment Centers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. South Korea
    • 8.5.6. Rest of Asia Pacific

9. Latin America CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. CASGEVY
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Sickle Cell Disease
    • 9.2.2. Transfusion-Dependent Beta Thalassemia
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adult
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Treatment Centers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. CASGEVY
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Sickle Cell Disease
    • 10.2.2. Transfusion-Dependent Beta Thalassemia
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adult
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals
    • 10.4.2. Specialty Treatment Centers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Vertex Pharmaceuticals Incorporated
    • 11.2.2. Intellia Therapeutics, Inc.
    • 11.2.3. Beam Therapeutics.
    • 11.2.4. Eli Lilly and Company (Verve Therapeutics, Inc.)
    • 11.2.5. CRISPR Therapeutics
    • 11.2.6. Editas Medicine

List of Tables

  • Figure 1: Global CRISPR Therapeutics Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
  • Figure 2: Global CRISPR Therapeutics Market Value Share (%), By Product, 2025 & 2034
  • Figure 3: Global CRISPR Therapeutics Market Value Share (%), By Indication, 2025 & 2034
  • Figure 4: Global CRISPR Therapeutics Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 5: Global CRISPR Therapeutics Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global CRISPR Therapeutics Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
  • Figure 8: North America CRISPR Therapeutics Market Value Share (%), By Product, 2025
  • Figure 9: North America CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
  • Figure 10: North America CRISPR Therapeutics Market Value Share (%), By Indication, 2025
  • Figure 11: North America CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
  • Figure 12: North America CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
  • Figure 13: North America CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
  • Figure 14: North America CRISPR Therapeutics Market Value Share (%), By End User, 2025
  • Figure 15: North America CRISPR Therapeutics Market Value (USD million), by Country, 2025 & 2034
  • Figure 16: North America CRISPR Therapeutics Market Value Share (%), by Country, 2025
  • Figure 17: Europe CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
  • Figure 18: Europe CRISPR Therapeutics Market Value Share (%), By Product, 2025
  • Figure 19: Europe CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
  • Figure 20: Europe CRISPR Therapeutics Market Value Share (%), By Indication, 2025
  • Figure 21: Europe CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
  • Figure 22: Europe CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
  • Figure 23: Europe CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
  • Figure 24: Europe CRISPR Therapeutics Market Value Share (%), By End User, 2025
  • Figure 25: Europe CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
  • Figure 28: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Product, 2025
  • Figure 29: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
  • Figure 30: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Indication, 2025
  • Figure 31: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
  • Figure 32: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
  • Figure 33: Asia Pacific CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
  • Figure 34: Asia Pacific CRISPR Therapeutics Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
  • Figure 38: Latin America CRISPR Therapeutics Market Value Share (%), By Product, 2025
  • Figure 39: Latin America CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
  • Figure 40: Latin America CRISPR Therapeutics Market Value Share (%), By Indication, 2025
  • Figure 41: Latin America CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
  • Figure 42: Latin America CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
  • Figure 43: Latin America CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
  • Figure 44: Latin America CRISPR Therapeutics Market Value Share (%), By End User, 2025
  • Figure 45: Latin America CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
  • Figure 48: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Product, 2025
  • Figure 49: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
  • Figure 50: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Indication, 2025
  • Figure 51: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
  • Figure 53: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global CRISPR Therapeutics Market Share (%), by Company, 2025